The Development Situation and Suggestions of RNA Therapy Industry

doi:10.13523/j.cb.2009037

China Biotechnology

2021, Vol. 41

Issue (2/3): 162-171 DOI: 10.13523/j.cb.2009037

The Development Situation and Suggestions of RNA Therapy Industry

YANG Ruo-nan,XU Li,XU Ping,SU Yan(

)

Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health,Chinese Academy of Sciences, Shanghai 200031, China

Download:

HTML

PDF(15901KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

In recent years, with a growing number of approved ASO and siRNA drugs, RNA therapy has gradually moved from clinical to industrial application, and RNA therapy currently can be applied to the treatment of rare diseases, tumors, infectious diseases and others. On the whole, a certain foundation on domestic RNA therapy industry has been built,while few engaged institutions, weak research pipelines and lacking of key technologies are still the main reasons that limit the development of RNA therapy industry in China. The development trends of RNA therapy industry at home and abroad are combed and analyzed, and then some suggestions for the development of RNA therapy in China are put forward.

Key words： ASO siRNA mRNA

Received: 27 September 2020 Published: 08 April 2021

ZTFLH:

Q52

Corresponding Authors: Yan SU E-mail: suyan@sibs.ac.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Ruo-nan YANG
	Li XU
	Ping XU
	Yan SU

Cite this article:

YANG Ruo-nan,XU Li,XU Ping,SU Yan. The Development Situation and Suggestions of RNA Therapy Industry. China Biotechnology, 2021, 41(2/3): 162-171.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2009037 OR https://manu60.magtech.com.cn/biotech/Y2021/V41/I2/3/162

Fig.1 RNA therapy technology system diagram

Fig.2 Key discoveries in RNA therapy

Fig.3 Delivery technology patent layout of major RNA therapy company

Fig.4 Important enterprises and related cooperative enterprises in the field of RNA therapy

Fig.5 Currently approved RNA therapy drugs

Fig.6 Number of RNA therapy drugs in development

Table 1 Approved ASO drugs

Table 2 ASOs of representative companies in phase III and NDA

Table 3 Approved siRNA drugs

Table 4 siRNAs of representative companies in phase III and NDA

Table 5 Preventive mRNA vaccines of representative companies in clinical

Table 6 Domestic progress of COVID-19 mRNA vaccines

Table 7 mRNA cancer vaccines of representative companies in clinical

Table 8 Protein-based mRNA therapeutics of Moderna in clinical


[1]	Kim Y K. RNA therapy: Current status and future potential. Chonnam Medical Journal, 2020,56(2):87-93. pmid: 32509554

[2]	Roberts T C, Langer R, Wood M J A . Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 2020,19(10):673-694. doi: 10.1038/s41573-020-0075-7 pmid: 32782413

[3]	Karikó K, Buckstein M, Ni H P, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005,23(2):165-175.

[4]	Hu B, Zhong L P, Weng Y H, et al. Therapeutic siRNA: state of the art. Signal Transduction and Targeted Therapy, 2020,5(1):1-25. doi: 10.1038/s41392-019-0089-y pmid: 32296011

[5]	Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. The New England Journal of Medicine, 2013,369(9):819-829. doi: 10.1056/NEJMoa1208760 pmid: 23984729

[6]	Hajj K A, Whitehead K A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nature Reviews Materials, 2017,2:17056.

[7]	Kranz L M, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016,534(7607):396-401.

[8]	Persano S, Guevara M L, Li Z Q, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials, 2017,125(4):81-89.

[9]	Pardi N, Hogan M J, Porter F W, et al. mRNA vaccines:a new era in vaccinology. Nature Reviews Drug Discovery, 2018,17(4):261-279. pmid: 29326426

[10]	Wang F, Zuroske T, Watts J K. RNA therapeutics on the rise. Nature Reviews Drug Discovery, 2020,19(7):441-442. pmid: 32341501

[11]	Viney N J, Van Capelleveen J C, Geary R S , et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet, 2016,388(10057):2239-2253.

[12]	Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, et al. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials, 2020,10(2):364.

[13]	Feldman R A, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine, 2019,37(25):3326-3334.

[14]	Kose N, Fox J M, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Science Immunology, 2019, 4(35):eaaw6647. DOI: 10.1126/sciimmunol.aaw6647.

[1]	LIU Shao-jin,FENG Xue-jiao,WANG Jun-shu,XIAO Zheng-qiang,CHENG Ping-sheng. Market Analysis and Countermeasures of Nucleic Acid Drugs in China[J]. China Biotechnology, 2021, 41(7): 99-109.

[2]	DUAN Yang-yang,ZHANG Feng-ting,CHENG Jiang,SHI Jin,YANG Juan,LI Hai-ning. The Effect of SIRT2 on Apoptosis and Mitochondrial Function in Parkinson’s Disease Model Cells Induced by MPP⁺[J]. China Biotechnology, 2021, 41(4): 1-8.

[3]	JING Hui-yuan,DUAN Er-zhen,DONG Wang. In Vitro Transcribed Self-amplifying mRNA Vaccines[J]. China Biotechnology, 2020, 40(12): 25-30.

[4]	HU Shun,YI You-jin,HU Tao,LI Fu-sheng. Development and Clinical Progress of mRNA Vaccine[J]. China Biotechnology, 2019, 39(11): 105-112.

[5]	Yang TAN,Sheng LIU,Feng-ling LUO,Xiao-lian ZHANG. *Analysis of Differential lncRNA Expression Profile in the Macrophages after Mycobacterium tuberculosis* Stimulation**[J]. China Biotechnology, 2018, 38(5): 1-9.

[6]	Jiao-rong QIN, Zhao ZHAO, Xin-mei LUO, Chun-yang LI. Increasing the Expression Level of Soluble Tumor Necrosis Factor Type I Based on Optimization of Secondary Structure of mRNA 5' Terminal TIR[J]. China Biotechnology, 2018, 38(3): 62-69.

[7]	Jin ZHANG,Dan SI,Zhi-bang YANG,Yu-xia XIONG,Lian-ju MA,Jin-yang LI,Ren-ju JIANG. Study on New Genes Associated with Dexamethasone Degradation[J]. China Biotechnology, 2018, 38(1): 15-24.

[8]	HU Na, LIU Qing, TANG Zhao-yong, TANG He-jing, AO Lan, ZHAO Zi-hao, FANG Liao-qiong. *siRNA Inhibits the Growth and Migration of Mouse Melanoma by MMP-9* and FAK Gene**[J]. China Biotechnology, 2016, 36(5): 34-39.

[9]	LI Zhen-hua, LI Cui-ping, ZHANG Xiang-qiang, DAI Li-ting, TANG Meng-si, WANG Guo-cai, JIANG Jian-wei, CAO Ming-rong. EM-3 Targets Stat3 to Induce Apoptosis, G₂/M Cell Cycle Arrest and Reduce the Proportion of SP Cells in Nasopharyngeal Carcinoma[J]. China Biotechnology, 2016, 36(3): 1-10.

[10]	YI Xue-rui, YUAN You-cheng, GONG Liang, ZHANG Xin-rui, LI Na, KONG Xiang-ping. The Inhibition of HBsAg of Natural Compounds and Bortezomib on Primary Hepatocytes of HBV-Tg Mice and the Proteome Analysis[J]. China Biotechnology, 2015, 35(11): 29-35.

[11]	TANG De-ping, MAO Ai-hong, WANG Fang, ZHANG Hong, WANG Li, LIAO Shi-qi. Targeted Delivery of siRNA Mediated by Aptamer Modified Liposome[J]. China Biotechnology, 2015, 35(1): 54-60.

[12]	XUE Yu-wen, LI Tie-jun, ZHOU Jia-ming, CHEN Li. The Application and Perspectives of Multi-target RNAi in the Research and Development of Gene Therapy[J]. China Biotechnology, 2015, 35(1): 75-81.

[13]	FU Hui, LI Fei-fei, MA Qiong, FU Huai-xiu, CUI Yu-fang, MAO Jian-ping. Experimental Screening mRNA Targets by Reverse Transcription for Ribozyme to GPA Expression Interference[J]. China Biotechnology, 2014, 34(3): 84-90.

[14]	LI Fei-fei, FANG Jing, MA Qiong, FU Hui, MAO Jian-ping. Natural Borneol Liquid Induced Cancer Cells Apoptosis[J]. China Biotechnology, 2013, 33(5): 22-27.

[15]	TANG De-ping, MAO Ai-hong, LIAO Shi-qi, XUE Lin-gui, ZHANG Bing-lin. The Types of siRNA Off-target Effects and the Strategies for Mitigation[J]. China Biotechnology, 2012, 32(07): 113-119.

Viewed

Full text

Abstract

Cited

Shared

Discussed